Microlife Microlife
  • Prodotti Domiciliari
    • BP A6 Advanced Easy_red_logo Pressione arteriosa
    • trasp_NON CONTACT Febbre
    • trasp_NEB NANO_half-acc_PRINT_LOcopy1 Terapia respiratoria
    • trasp_WS 80n_half Controllo del peso
    • Software_downloads_allg Software
  • Prodotti Professionali
    • WatchBP Office ABI_front_cuff WatchBP Office
    • WatchBP O3 Ambulatory AFIB_front_cuff WatchBP 03
    • WatchBP Home A_front_cuff WatchBP Home
    • Cuff-Ankle Bracciali e Accessori
    • Software Software
  • Tecnologie
  • Magazine
  • Azienda
    • aboutus Chi siamo
    • Events Eventi e News
    • contact Contatti
    • History Storia
ITALIA
Italiano
Europe
  • EUROPE - English
  • CZECHIA - Čeština
  • DANMARK - Dansk
  • DEUTSCHLAND - Deutsch
  • ESPAÑA - Español
  • FRANCE - Français
  • HRVATSKA - Hrvatski
  • ITALIA - Italiano
  • LATVIJA - Latviešu
  • LIETUVA - Lietuvių
  • MAGYARORSZÁG - Magyar
  • NEDERLAND - Nederlands
  • ÖSTERREICH - Deutsch
  • POLSKA - Polski
  • PORTUGAL - Português
  • SCHWEIZ - Deutsch
  • SLOVENSKO - Slovenčina
  • SLOVENIJA - Slovenščina
  • SUOMI - Suomi
  • SCHWEIZ - Français
  • UK - English
  • ΕΛΛΆΔΑ - Ελληνικά
  • БЪЛГАРИЯ - Български
  • СРБИЈА - Српски
  • УКРАЇНА - Українська
  • TÜRKIYE - Türkçe
  • РОССИЯ - Русский
  • БЕЛАРУСЬ - Русский
Asia
  • ASIA PACIFIC - English
  • VIỆT NAM - Tiếng Việt
  • ประเทศไทย - ไทย
  • 中国 - 中文
  • 台灣 - 中文
Middle East and North Africa
  • MENA - Arabic عربى
USA, Latin America
  • US - English
  • AMÉRICA DEL SUR - Español
  • COLOMBIA - Español
  • MÉXICO - Español
Menu
Header Microlife & WatchBP Clinical Studies Flow

Comparison of the Microlife blood pressure monitor with the Omron blood pressure monitor for detecting atrial fibrillation

Home > Prodotti Professionali
Share

2014, Joseph Wiesel, MDa*, Benjamin Arbesfeld, MDb, and David Schechter, MDc

Abstract

Screening for atrial fibrillation (AF) by assessing the pulse is recommended in high-risk patients. Some clinical trials demonstrated that the Microlife blood pressure monitor (BPM) with AF detection is more accurate than pulse palpation. This led to a change in practice guidelines in the United Kingdom where AF screening with the Microlife device is recommended instead of pulse palpation. Many BPMs have irregular heart beat detection, but they have not been shown to detect AF reliably. Recently, one study, in a highly select population, suggested that the Omron BPM with irregular heart beat detection has a higher sensitivity for AF than the Microlife BPM. We compared the Microlife and Omron BPMs to electrocardiographic readings for AF detection in general cardiology patients. Inclusion criteria were age ‡50 years without a pacemaker or defibrillator. A total of 199 subjects were enrolled, 30 with AF. Each subject had a 12-lead electrocardiography, 1 Omron BPM reading, and 3 Microlife BPM readings as per device instructions. The Omron device had a sensitivity of 30% (95% confidence interval [CI] 15.4% to 49.1%) with the sensitivity for the first Microlife reading of 97% (95% CI 81.4% to 100%) and the Microlife readings using the majority rule (AF positive if at least 2 of 3 individual readings were positive for AF) of 100% (95% CI 85.9% to 100%). Specificity for the Omron device was 97% (95% CI 92.5% to 99.2%) and for the first Microlife reading of 90% (95% CI 83.8% to 94.2%) and for the majority rule Microlife device of 92% (95% CI 86.2% to 95.7%; p <0.0001). The specificity of both devices is acceptable, but only the Microlife BPM has a sensitivity value that is high enough to be used for AF screening in clinical practice.

 ©2014 Elsevier Inc. All rights reserved. (Am J Cardiol 2014;114:1046e1048)

Download Abstract as PDF-file

Click here to read this article on PubMed

Microlife
  • Contatti
  • Sede Legale
  • Privacy & Cookie Policy
  • Termini di utilizzo
  • Sviluppatori
Login
Copyright © 2025 - Microlife Corporation. All rights reserved.